These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 34871862)
1. miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux. Jain N; Das B; Mallick B DNA Repair (Amst); 2022 Jan; 109():103259. PubMed ID: 34871862 [TBL] [Abstract][Full Text] [Related]
2. miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells. Jin Y; Wang H; Zhu Y; Feng H; Wang G; Wang S Eur J Pharmacol; 2020 Jul; 878():173105. PubMed ID: 32278855 [TBL] [Abstract][Full Text] [Related]
3. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A. Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143 [TBL] [Abstract][Full Text] [Related]
4. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008 [TBL] [Abstract][Full Text] [Related]
5. piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair. Das B; Jain N; Mallick B Commun Biol; 2021 Nov; 4(1):1312. PubMed ID: 34799689 [TBL] [Abstract][Full Text] [Related]
7. miR-197-5p inhibits sarcomagenesis and induces cellular senescence via repression of KIAA0101. Jain N; Roy J; Das B; Mallick B Mol Carcinog; 2019 Aug; 58(8):1376-1388. PubMed ID: 31001891 [TBL] [Abstract][Full Text] [Related]
8. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. Feng DD; Zhang H; Zhang P; Zheng YS; Zhang XJ; Han BW; Luo XQ; Xu L; Zhou H; Qu LH; Chen YQ J Cell Mol Med; 2011 Oct; 15(10):2164-75. PubMed ID: 21070600 [TBL] [Abstract][Full Text] [Related]
9. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer. Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481 [TBL] [Abstract][Full Text] [Related]
10. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway. Li X; He J; Ren X; Zhao H; Zhao H Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276 [TBL] [Abstract][Full Text] [Related]
11. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer. Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033 [TBL] [Abstract][Full Text] [Related]
12. MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte. Wan GX; Cheng L; Qin HL; Zhang YZ; Wang LY; Zhang YG Cardiovasc Toxicol; 2019 Jun; 19(3):264-275. PubMed ID: 30535663 [TBL] [Abstract][Full Text] [Related]
13. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937 [TBL] [Abstract][Full Text] [Related]
14. Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. Lehnhardt M; Klein-Hitpass L; Kuhnen C; Homann HH; Daigeler A; Steinau HU; Roehrs S; Schnoor L; Steinstraesser L; Mueller O BMC Cancer; 2005 Jul; 5():74. PubMed ID: 16001973 [TBL] [Abstract][Full Text] [Related]
15. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22. Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291 [TBL] [Abstract][Full Text] [Related]
16. Synergistic Therapy of Doxorubicin and miR-129-5p with Self-Cross-Linked Bioreducible Polypeptide Nanoparticles Reverses Multidrug Resistance in Cancer Cells. Yi H; Liu L; Sheng N; Li P; Pan H; Cai L; Ma Y Biomacromolecules; 2016 May; 17(5):1737-47. PubMed ID: 27029378 [TBL] [Abstract][Full Text] [Related]
17. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma. Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055 [TBL] [Abstract][Full Text] [Related]
18. MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism. Pan C; Wang X; Shi K; Zheng Y; Li J; Chen Y; Jin L; Pan Z PLoS One; 2016; 11(5):e0152090. PubMed ID: 27138141 [TBL] [Abstract][Full Text] [Related]
19. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. Shaik MS; Chatterjee A; Singh M J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869 [TBL] [Abstract][Full Text] [Related]
20. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1. Long X; Lin XJ J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]